Ataxia therapies: What works, what’s new, and what’s next Ataxias remain among the most therapeutically frustrating disorders in neurology — but recent advances suggest a meaningful shift in the treatment landscape.

Ataxias remain among the most therapeutically frustrating disorders in neurology — but recent advances suggest a meaningful shift in the treatment landscape. #PASCongress https://loom.ly/2tJFVmM

Follow along and test your knowledge alonside Dr. Ai Huey Tan as she breaks down the phenomenology, family history, and laboratory findings of a 21-year-old man with deafness-dystonia syndrome. loom.ly/li8i3pw

Integrated care in movement disorders: Multidisciplinary models for better outcomes Practical tools and approaches to address a ‘new era’ of PwP — and the real-world examples where they are already working.

Practical tools and approaches to address a ‘new era’ of PwP — and the real-world examples where they are already working. #PASCongress https://loom.ly/gAq1HUg

RAB32-linked Parkinson's disease: Deep phenotyping, MDSGene literature review, and application of SynNeurGe criteria Study provides the first evidence for misfolded α-synuclein pathology in PARK-RAB32.

MDS Young Member Group highlight:
New study provides the first evidence for misfolded α-synuclein pathology in PARK-RAB32. https://loom.ly/nd5BtAU

Final chance to watch key highlights from the 2025 International Congress. View on demand sessions » https://loom.ly/HwApqPA

Speech & Language Therapists: Become a local trainer
13-month specialty program to help you teach your local colleagues about movement disorders care. https://loom.ly/ZGS3Dbs

Learn to spot (and interpret) this critical early clue to a wide range of neurologic conditions, some of which are treatable. https://loom.ly/8QjJ_ds

AI is just a tool, but it matters how we use it Experts delve into how AI works, how our field has already incorporated it into clinical practice and research, and how it may be able to bridge the North-South gap.

Experts delve into how AI works, how our field has already incorporated it into clinical practice and research, and how it may be able to bridge the North-South gap. #PASCongress loom.ly/qRIEzys

MDS-ES/EAN Sessions at EAN Congress MDS-EAN Education Workshops

Engage with expert-led video discussions in movement disorders during the MDS-ES European Basal Ganglia Club special session at the 12th EAN Congress. #MDSatEAN https://loom.ly/e5kV1u8

Last chance: Register for the 5th Movement Disorders Clinical Practice Conference on May 10 in Lübeck, Germany. https://loom.ly/bqTr8Zw

Continuing the ataxia series, Dr. Divyani Garg breaks down how to clinically approach sporadic ataxias, including what to look for during examination, family history, and imaging and laboartory tests. https://loom.ly/6IuXdsk

From patient to research: Exploring a four-strain probiotic's effects in Parkinson’s disease SymPD trial findings suggest a four-strain probiotic can beneficially modulate gut microbiota, with potential downstream effects.

SymPD trial findings suggest a four-strain probiotic can beneficially modulate gut microbiota, with potential downstream effects. Read more: https://loom.ly/GKhFZKE

In honor of #WorldParkinsonsDay, let's acknowledge James Parkinson — the first person to document "paralysis agitans," now known as Parkinson's disease, within his work "An Essay on the Shaking Palsy."

Stanley Fahn and C. David Marsden were some of the earliest advocates of Parkinson’s disease and other movement disorders. They were both pivotal leaders and visionaries in the science and care of PD and founded MDS in 1985.

How do you advocate for #PD?
#worldparkinsonsday

In honor of #worldparkinsonsday, lets acknowledge some of the researchers and clinicians who have advanced our understanding of PD.

Identified alpha-synuclein as a major component of Lewy bodies, clumps of proteins found in Parkinson’s disease and dementia with Lewy bodies.

In honor of #worldparkinsonsday, lets acknowledge some of the researchers and clinicians who have advanced our understanding of PD.

Developed deep brain stimulation for treatment in Parkinson’s disease by first testing in the thalamus but then moving to the subthalamic nucleus.

In honor of #worldparkinsonsday, lets acknowledge some of the researchers and clinicians who have advanced our understanding of PD.

Linked dopamine deficiency to Parkinson’s disease and was influential in creating the first L-dopa clinical trials.

In honor of #worldparkinsonsday, lets acknowledge some of the researchers and clinicians who have advanced our understanding of PD.

The first people to develop a rating scale for PD patients, the Hoehn and Yahr scale, which includes 5 stages of disease progression.

In honor of #worldparkinsonsday, lets acknowledge some of the researchers and clinicians who have advanced our understanding of PD.

Advanced understanding of PD by distinguishing between rigidity, weakness, and bradykinesia. Formally renamed PD after James Parkinson.

Scientific advancements compound on each other. Take a look at some of the major milestones of PD research and treatment that have paved the way for the current state of patient care and research. #worldparkinsonsday

You are likely to see tremor, even in primary care.

Improve your recognition and gain practical therapeutic approaches for the most common movement disorder. https://loom.ly/ZKUiLF4

Women hold fewer leadership roles and report less access to administrative support, while men report receiving less faculty mentoring, per a survey of MDS members conducted by the Women in Movement Disorders Special Interest Group. https://loom.ly/oEH_Rew

Tomatoes and Parkinson’s disease: An old hypothesis revisited An originally tongue-in-cheek proposal may have been less far-fetched than originally thought.

An originally tongue-in-cheek proposal may have been less far-fetched than originally thought. Learn more: https://loom.ly/H0fZb9o

Can low-dose carbon monoxide treat Parkinson’s disease? Innovative LoCaMoTE-PD Phase 2A trial explores possible explanation for neuroprotective benefits of smoking.

Innovative LoCaMoTE-PD Phase 2A trial explores possible explanation for neuroprotective benefits of smoking. https://loom.ly/O87Bpcc

How neuroimaging is rapidly transforming the diagnosis and treatment of Parkinson’s disease Experts share how multimodal and alpha-synuclein imaging can offer deeper insights into subtle neurodegeneration across the disease spectrum.

Experts share how multimodal and alpha-synuclein imaging can offer deeper insights into subtle neurodegeneration across the disease spectrum. #PASCongress https://loom.ly/W8tuu3Q

Gain practical insights across the full treatment journey, from setting expectations to dose escalation, pattern adjustment, and troubleshooting. https://loom.ly/zKRfeLQ

The history of videography dates back over 100 years. Dr. Mattia Rosso shares the interesting overlap of videography and neurology, and how they have evolved together to influence movement disorder clinical practice and education. https://loom.ly/VxDEuT0

Seminal reviews stress the dangers of swallowing problems in people with Parkinson’s disease Moving Along

Two recent publications highlight the need for large, well-designed studies on links with medication intake, hospitalization, and aspiration pneumonia. Read now: https://loom.ly/CwBCEXk

Combined dysfunction of the amygdala and nucleus basalis underlies visual hallucinations in Parkinson's disease Findings support network-based models proposing that visual hallucinations emerge from disrupted coordination between visual and attentional systems.

MDS Young Member Group highlight:
New findings support network-based models proposing that visual hallucinations emerge from disrupted coordination between visual and attentional systems. https://loom.ly/tBc3unE

If you work with people with movement disorders in any health capacity, this flagship course will give you practical, actionable tools to improve their lives. https://loom.ly/cuegghw